Hemispherx Biopharma Inc (HEB) - Financial and Strategic SWOT Analysis Review

Hemispherx Biopharma Inc (HEB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hemispherx Biopharma Inc (Hemispherx) is an immune- pharma company focuses on the research and development of therapeutics in the treatment of multiple types of cancers. Its flagship products include Rintatolimod (Rintamod or Ampligen) and Alferon N Injection. Rintatolimod is an US-FDA approved drug indicated for the treatment of various disorders of immune system and different types of solid tumors. Rintatolimod is also being evaluated for myalgic encephalomyelitis/chronic fatigue syndrome. Alferon N Injection is Argentina and US-FDA approved drug in the treatment of Genital HPV. The company operates production facility in New Brunswick, New Jersey. Hemispherx is headquartered in Orlando, Florida, the US.

Hemispherx Biopharma Inc Key Recent Developments

Jun 28,2019: Hemispherx Biopharma CFO Adam Pascale announces retirement
May 16,2019: Hemispherx Reports 2019 First Quarter Financial Results
Apr 22,2019: Hemispherx Biopharma appoints Ellen Lintal as new chief accounting officer
Apr 01,2019: Hemispherx reports 2018 year-end financial results
Jan 23,2019: Hemispherx Biopharmas CEO to present at the 15th Annual NobleConXV Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


List of Tables
List of Figures
Section 1 - About the Company
Hemispherx Biopharma Inc - Key Facts
Hemispherx Biopharma Inc - Key Employees
Hemispherx Biopharma Inc - Key Employee Biographies
Hemispherx Biopharma Inc - Major Products and Services
Hemispherx Biopharma Inc - History
Hemispherx Biopharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Hemispherx Biopharma Inc - Business Description
Hemispherx Biopharma Inc - SWOT Analysis
SWOT Analysis - Overview
Hemispherx Biopharma Inc - Strengths
Hemispherx Biopharma Inc - Weaknesses
Hemispherx Biopharma Inc - Opportunities
Hemispherx Biopharma Inc - Threats
Hemispherx Biopharma Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Hemispherx Biopharma Inc, Recent Deals Summary
Section 5 Companys Recent Developments
Jun 28, 2019: Hemispherx Biopharma CFO Adam Pascale announces retirement
May 16, 2019: Hemispherx Reports 2019 First Quarter Financial Results
Apr 22, 2019: Hemispherx Biopharma appoints Ellen Lintal as new chief accounting officer
Apr 01, 2019: Hemispherx reports 2018 year-end financial results
Jan 23, 2019: Hemispherx Biopharmas CEO to present at the 15th Annual NobleConXV Conference
Dec 26, 2018: Hemispherx Biopharma issues business update to clarify apple iOS12 stocks application no recent stories misinformation
Nov 15, 2018: Hemispherx Reports 2018 Third Quarter and First Nine Months Financial Results
Aug 15, 2018: Hemispherx announces six months ended June 30, 2018 financial results
May 16, 2018: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update
May 14, 2018: Hemispherx to Present at the 4th Annual Immuno-Oncology: BD&L and Investment Forum
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables


Hemispherx Biopharma Inc, Key Facts
Hemispherx Biopharma Inc, Key Employees
Hemispherx Biopharma Inc, Key Employee Biographies
Hemispherx Biopharma Inc, Major Products and Services
Hemispherx Biopharma Inc, History
Hemispherx Biopharma Inc, Subsidiaries
Hemispherx Biopharma Inc, Key Competitors
Hemispherx Biopharma Inc, Ratios based on current share price
Hemispherx Biopharma Inc, Annual Ratios
Hemispherx Biopharma Inc, Annual Ratios (Cont...1)
Hemispherx Biopharma Inc, Interim Ratios
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Hemispherx Biopharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures


Hemispherx Biopharma Inc, Performance Chart (2014 - 2018)
Hemispherx Biopharma Inc, Ratio Charts
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Hemispherx BioPharma Inc Strategic Analysis Review- Hemispherx BioPharma Inc SWOT, Outlook, Operations and Financial Profile

Hemispherx BioPharma Inc Company Profile provides strategic analysis of Hemispherx BioPharma Inc Company in current market conditions. The companys business/ operational/growth strategies are analyzed in the unique research work. Growth

USD 200 View Report

Hemispherx Biopharma Inc (HEB) - Financial and Strategic SWOT Analysis Review

Hemispherx Biopharma Inc (HEB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

PDL BioPharma Inc - Strategic SWOT Analysis Review

PDL BioPharma Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information

USD 125 View Report

Seneca Biopharma Inc (CUR) - Financial and Strategic SWOT Analysis Review

Seneca Biopharma Inc(Seneca) formerly known as Neuralstem Inc, is a biopharmaceutical company that develops novel treatments for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke,

USD 300 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available